Archives Des Press Release

19/09/202420/09/2024

Avicenna.AI lands FDA clearance for AI tool for cervical spine fracture detection

Medical imaging AI company receives approval for CINA-CSpine algorithm enabling detection and triage of cervical spine fractures.

La Ciotat, FRANCE – September 19, 2024 – Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-CSpine tool. Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.

CINA-CSpine is an AI tool designed to support the detection and triage of cervical spine fractures from CT images. Commonly caused by traumatic injury, a cervical spine fracture is a break in one or more of the seven vertebrae in the neck that can lead to spinal cord injury, resulting in neurological damage or even paralysis.

While the prognosis for cervical spine fractures depends on the severity of the injury, the timeliness of treatment is key, so prompt detection and appropriate treatment are crucial for optimizing outcomes and minimizing long-term complications. CINA-CSpine automatically flags suspected positive findings compatible with acute cervical spine fractures, seamlessly alerting radiologists through their existing systems.

“Cervical spine fractures are serious injuries that require prompt and appropriate medical attention, especially if the spinal cord is involved, so accurate diagnosis is essential,” said Cyril Di Grandi, co-founder and CEO of Avicenna.AI. “With CINA-CSpine, we aim to help reduce the delay between scan and interpretation, which is critical in the treatment of this condition.”

In addition, while missed findings are relatively rare, failure to diagnose a cervical spine injury is frequently subject to litigation. With average legal costs in the US estimated to be around $3 million, and settlements reaching as high as $9 million, an AI tool like CINA-CSpine can provide a second set of eyes to help avoid missed findings.

CINA-CSpine was validated on more than 300 non-contrast CT scans provided by multiple sources in the US and Europe, and acquired from 36 different scanner models across five vendors. The device achieved an overall sensitivity and specificity of 90.3% and 91.9%, respectively, when compared to the ground truth established by the consensus of three US-board certified senior radiologists.

“These results demonstrate that our CINA-CSpine algorithm is capable of providing prompt and accurate findings that could positively guide physicians towards better assessments and improved patient outcomes,” added Di Grandi.

CINA-CSpine is the latest tool from Avicenna.AI to secure FDA clearance, joining its AI solutions for automatic detection of a host of conditions from CT-scan imaging. All of the company’s AI tools are seamlessly integrated into radiologists’ clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists.

Avicenna.AI’s product portfolio also includes seven other AI tools for the prevention and detection of:

Intracranial hemorrhage (CINA-ICH)
Large vessel occlusion (CINA-LVO)
Aortic dissection (CINA-AD)
Pulmonary embolism (CINA-PE and CINA-iPE)
Vertebral compression fractures (CINA-VCF)
And ASPECT Score for quantification of stroke severity (CINA-ASPECTS).

About Avicenna.AI
Founded in 2018, Avicenna.AI specializes in providing healthcare AI solutions that utilize deep learning to identify, detect, and quantify severe pathologies from CT medical images. Co-founded by Cyril Di Grandi, a successful entrepreneur who previously co-founded Olea Medical, and Dr. Peter Chang, an internationally recognized radiologist, and an expert in AI and deep learning, Avicenna.AI aims to accelerate therapeutic decision-making processes and enhance patient outcomes through its AI-based radiology solutions. For additional details, stay connected with us on social media and explore Avicenna.AI’s website at www.avicenna.ai.

For more information, contact:

Stéphanie Bellavia, Marketing Manager, Avicenna.AI
Email: stephanie.bellavia@avicenna.ai

03/07/202403/07/2024

Avicenna.AI secures Medical Device Regulation certification for medical imaging AI portfolio

French AI company achieves key EU regulatory compliance for multiple algorithms that identify, detect, and quantify severe conditions from medical images.

La Ciotat, FRANCE – July 3, 2024 – Avicenna.AI, a leading medical imaging AI company, has received Medical Device Regulation (MDR) certificate for five of its algorithms from certification body BSI Medical Devices. This development means the company’s product portfolio is fully compliant with the European Union’s MDR 2017/745, which is now mandatory for medical device companies that want to provide their solutions in Europe.

The MDR was introduced to update the EU’s regulations for medical devices, addressing safety issues and the recent emergence of AI tools and software as a medical device (SaMD), which did not exist when the old regulations were created. Ensuring MDR compliance is a critical component of obtaining and maintaining CE-mark status, which allows a device to be freely traded in the EU.

Compared to the previous Medical Device Directive (MDD), the MDR has a wider scope and more stringent requirements. It emphasizes clinical evaluation, post-market surveillance, device traceability, rigorous technical documentation, and risk management. These measures aim to enhance patient safety and ensure high standards for medical devices, including AI and software-based solutions.

Avicenna.AI’s products have been certified as Class IIb medical devices, which requires a high level of clinical validation. The certified products include the company’s suite of AI tools for neurovascular conditions, as well as its suite of algorithms for vascular conditions.

“Obtaining MDR certification is a significant milestone for Avicenna.AI. It demonstrates our commitment to meeting the highest standards of medical device safety and performance. This certification not only reinforces our dedication to compliance but also assures our customers of the quality and reliability of our AI product portfolio,” said Stéphane Berger, Regulatory Manager at Avicenna.AI.

The company’s MDR-certified AI tools include algorithms for intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), quantification of stroke severity (CINA-ASPECTS), aortic dissection (CINA-AD), pulmonary embolism (CINA-PE), and opportunistic cases of pulmonary embolism (CINA-iPE). All the products are also CE-marked and FDA-cleared.

“Crucially, despite the differences in SaMD regulatory requirements between authorities in the US and Europe, we are consistently achieving both FDA and CE mark clearance for our AI products,” added Berger.

All of Avicenna.AI’s AI tools are seamlessly integrated into radiologists’ clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists.

12/06/202403/07/2024

Avicenna.AI secures FDA clearance for AI detection of vertebral compression fractures

$radiologist explains to a patient about the diagnosis of vertebral compression fracture$

Medical imaging AI company receives approval for algorithm enabling opportunistic detection and triage of vertebral compression fractures.

La Ciotat, FRANCE – June 12, 2024 – Avicenna.AI, a leading medical imaging AI company, has received 510(k) clearance from the US Food and Drug Administration (FDA) for CINA-VCF, a triage and notification AI tool that detects unsuspected vertebral compression fractures (VCFs) in patients undergoing chest or abdomen CT scans.

Often resulting from the deterioration of bone structure (osteoporosis), VCFs can cause significant pain, deformity, and height loss. In the USA, approximately 750,000 adults suffer from osteoporotic VCFs each year, but around two-thirds of those go undetected or unreported.

The CINA-VCF algorithm identifies and prioritizes vertebral compression fractures detected during routine CT scans for patients undergoing medical imaging for entirely different health conditions, notifying clinicians within seconds. The tool was validated on 474 CT scans (performed for other clinical indications than for VCF evaluation) acquired on 38 different scanner models from four different manufacturers, achieving excellent sensitivity and specificity results.

By facilitating the early detection of vertebral compression fractures, CINA-VCF aims to help prevent further bone density loss and additional fractures, enhancing patient care and outcomes. The tool enables vertebral fractures to be addressed before they multiply, reducing the risk of complications and potentially lowering medical expenses.

“Osteoporosis is a global burden affecting millions, especially postmenopausal women, and often goes unnoticed until symptoms like pain and loss of mobility appear,” said Cyril Di Grandi, co-founder and CEO of Avicenna.AI. “By detecting vertebral compression fractures early, we aim to help patients maintain better mobility and independence, enhance the well-being of those at risk, and reduce the burden on healthcare systems worldwide. We have also partnered with the International Osteoporosis Foundation to increase awareness about this debilitating condition.”

CINA-VCF is the latest tool from Avicenna.AI to secure FDA clearance, joining its AI solutions for automatic detection of a host of conditions from CT imaging. It is also the company’s second tool FDA-cleared for incidental findings, alongside CINA-iPE, which identifies unsuspected cases of pulmonary embolism in oncology patients.

The company’s other AI tools include algorithms for intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), aortic dissection (CINA-AD), pulmonary embolism (CINA-PE), and quantification of stroke severity (CINA-ASPECTS). All of Avicenna.AI’s AI tools are seamlessly integrated into radiologists’ clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists

26/04/202203/07/2024

Avicenna.AI signs a distribution agreement with Sectra for neurovascular AI solutions

La Ciotat, France– April 27, 2022 – Medical imaging AI specialist Avicenna.AI today announced a signed distribution agreement with Sectra, an international medical imaging IT and cybersecurity company. The agreement will see Avicenna’s AI solutions for neurovascular pathologies offered through the Sectra Amplifier Marketplace, a platform for contracting, purchasing, and servicing of AI applications validated and verified for use at point of care.

Avicenna’s CINA solutions use deep learning to identify, detect and quantify life-threatening pathologies from CT medical images. The FDA-cleared and CE-Marked tools are seamlessly integrated within the clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists.

Stroke is a leading cause of long-term disability and the second leading cause of death, with one death every 6 seconds worldwide. There are two main types of strokes: ischemic stroke, caused by a blood clot (LVO), and hemorrhagic stroke, caused by an intracranial hemorrhage (ICH).

The AI tools to be included in Sectra’s Amplifier Marketplace include CINA-ICH, CINA-LVO, and CINA-ASPECTS.

CINA-ICH uses deep learning to identify suspected intracranial hemorrhage and prioritizes those cases in the worklist, dramatically reducing turnaround time for head trauma and stroke patients. (US/EU)
CINA-LVO is a triage tool for rapid automatic LVO detection and real-time triage and prioritization, accelerating clinical workflow and helping stroke teams in their diagnosis. (US/EU)
CINA-ASPECTS is an AI-based automatic quantification tool that enables faster, more consistent, and more precise interpretation for the assessment of acute ischemic stroke. (available for European Union only)

Using a combination of deep learning and machine learning technologies, the CINA solutions automatically detect and prioritize acute ICH and LVO cases within seconds, and assess them for severity, seamlessly alerting radiologists within their existing systems and workflow.

“To help healthcare providers get on the AI adoption journey, we have created the Sectra Amplifier Marketplace. We aim to facilitate easier access and usage of AI applications in medical imaging. This distribution agreement is an example of that. With Avicenna.AI tools deeply embedded in the Sectra diagnostic workspace, we provide our radiologists with enhanced diagnostic confidence for stroke cases,” says Nynke Breimer, Global Product Manager AI Radiology, Sectra.”

“We provide best-in-class AI triage tools that enable fast detection of the leading causes of stroke, leading to more efficient patient management,” said Cyril Di Grandi, co-founder, and CEO of Avicenna.AI. “We are glad to collaborate with a global partner such as Sectra. Through this agreement, we can help more clinicians to facilitate stroke decision making, ensuring a prompt therapeutic response and ultimately improving patient outcomes.”

About Avicenna.AI
Founded in 2018, Avicenna.AI develops medical imaging AI solutions for highly prevalent pathologies. The company uses artificial intelligence and deep learning to optimize many of a radiologist’s manual tasks. Its CINA products leverage deep learning algorithms to identify acute abnormalities and support emergency room triage. Avicenna.AI is co-founded by Cyril Di Grandi, who previously co-founded and successfully sold Olea Medical, and Dr. Peter Chang, a radiologist and internationally recognized expert in AI and deep learning.

About Sectra
With 30 years of innovation and more than 2,000 installations around the globe, Sectra is a leading imaging IT provider for health systems worldwide. Sectra offers a complete enterprise solution comprised of imaging modules (radiology, cardiology, pathology, orthopedics, and ophthalmology), and a robust VNA. Over the last nine consecutive years, Sectra has been awarded Best in KLAS for the highest customer satisfaction. For more information, visit Sectra website.

27/07/202103/07/2024

Avicenna.AI partners UpCare for innovative value-based solutions to Canadian health providers

Toronto & Marseille – July 27^th , 2021 –Medical imaging AI specialist Avicenna.AI today announced a partnership with UpCare Partners & Associates to distribute, deliver and implement a fully integrated stroke detection AI solution for any PACS Platform in Canada.

With this partnership, Avicenna provides UpCare with its FDA-approved CINA Head triage AI solution for neurovascular emergencies, which detects two of the leading causes of stroke – intracranial hemorrhage (ICH) and large vessel occlusion (LVO) – from CT-scan imaging.

Using a combination of deep learning and machine learning technologies, CINA Head automatically detects and prioritizes acute ICH and LVO cases within 20 seconds, seamlessly alerting the radiologist within their existing systems and workflow.

CINA’s ICH detection capability was validated using data from 814 cases conducted at more than 250 imaging centers across the United States, with 96% accuracy, 91.4% sensitivity and 97.5% specificity. The product’s LVO detection capability was validated based on 476 cases, with 97.7% accuracy 97.9% sensitivity and 97.6% specificity.

“Canada is a Leading Country in the world of Neuroscience, the partnership will enrich physicians’ resources for accessing and qualifying Stroke events and ICH seamlessly in a record time; we are always looking to provide our customers with enhanced and expanded imaging capabilities” said Benoit Sai, Co-Founder & CCO, UpCare Partners & Associates. “By adding Avicenna’ proven and validated solutions to our Neuroscience ecosystem, Canadian healthcare providers have access to innovative automated advanced brain imaging technology, allowing them to deliver better patient care.”

Cyril Di Grandi, co-founder and CEO, Avicenna.AI, said, “Our partnership with a Canadian distributor focussing on ecosystems approach toward the continuum of care in the field of neurosciences combined with expertise in medical imaging, medical devices and ai like UpCare Inc is a testament to the excellent accuracy, sensitivity and specificity data that has been gathered during our validation phase. We look forward to working with our new partner to bring the benefits of our AI-powered stroke triage solution to the emergency room and beyond in Canada.”

About UpCare Partners & Associates
Founded in 2019, UpCare Partners & Associates, a Canadian MedTech Company, is the gateway to the Canadian market for start-ups and international OEM. The company provides the best expertise in each field by committing special attention and a focussed approach to your product on a Pan Canada basis. In this challenging time for Healthcare Institutions UpCare Partners & Associates works with its partners on Value Based Solutions for the best Patient Outcome and Continuum of Care. www.upcarepartners.com

15/07/202103/07/2024

Viz.ai and Avicenna.AI Launch AI Care for Pulmonary Embolism & Aortic Disease

San Francisco and Paris – July 15, 2021 – Viz.ai, the world leader in AI-driven intelligent care coordination has partnered with Avicenna.AI, a global leader in artificial intelligence solutions, to enable intelligent care coordination and improve patient triage of patients suffering from pulmonary embolism (PE) and aortic disease (AD). The collaboration will pave the way for faster clinical decision making and care for patients suffering from these two life threatening conditions.

Diagnosis and care coordination of patients suffering from PE and aortic disease can be challenging. Avicenna.AI’s FDA-approved algorithms for PE and Type A and Type B aortic dissection (AD), leveraged on the Viz intelligent care coordination platform, will empower multidisciplinary care teams to easily coordinate patient care by sending notifications paired with dynamic imaging and detailed patient information to each provider’s desktop or mobile device as soon as a PE or an aortic dissection is detected. As part of Viz.ai’s commercial aortic module offering, access to imaging and workflows supporting the coordination of care for patients with abdominal aortic aneurysm (AAA), thoracic aortic aneurysm (TAA), rupture, stenosis and transection will be available in addition to the AD algorithm. Similarly, the PE algorithm will be available on Viz.ai’s commercial PE module.

“The addition of AI powered workflows should decrease the time from diagnosis to treatment and help to coordinate care for patients suffering from life-threatening PE and aortic disease, as it has in the treatment of ischemic stroke. It will help to facilitate faster and easier treatment decisions across health systems, and this should improve outcomes for patients,” said Dr. Richard Saxon, interventional radiologist Tri-City Medical Center.

The Viz Platform is clinically proven and validated by Medicare, which reimburses hospitals directly via a New Technology Add-On Payment for Viz LVO, the time-saving ischemic stroke product. Pairing team alerts enhanced by AI with high-fidelity mobile image viewing, patient information and full-stack secure communication enables multidisciplinary teams to make faster treatment decisions for patients. The result increases access to care and improves outcomes for patients.

“We are proud to become a trusted partner of Viz.ai, who is committed to giving access to high-standard healthcare systems worldwide. Thanks to our AI-based solutions, we hope to facilitate an optimal medical response within a short time frame and improve patient care. We look forward to bringing the benefits of our pulmonary embolism and aortic dissection triage tools to the emergency room and beyond,” said Cyril Di Grandi, chief executive officer of Avicenna.AI.

PE is a potentially deadly form of venous thromboembolic disease, a common cause of cardiovascular death, and is associated with multiple inherited and acquired risk factors affecting hundreds of thousands of people every year globally. PE occurs when a blood clot gets lodged in an artery in the lung, blocking blood flow to part of the lung. Similar to PE, aortic disease is potentially deadly and can require urgent surgical intervention to prevent death.

“We’re delighted to partner with Avicenna to bring intelligent care coordination to the peripheral vascular and vascular fields. This will form part of a broader Viz.AI platform, where any patient with life threatening diseases can benefit from AI powered triage, fast mobile communication and synchronized care coordination,” said Dr. Chris Mansi, Viz.ai CEO and co-founder. “This partnership will bring the advantages of artificial intelligence to more patients and help hospitals achieve better clinical outcomes.”

About Viz.ai, Inc.
Viz.ai is the leader in AI-driven intelligent care coordination. Viz.ai’s mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment, improve access to care, and increase the speed of diffusion of medical innovation. Viz.ai’s clinically validated platform leverages advanced deep learning to communicate time-sensitive information to specialists who can more quickly and easily make treatment decisions for the patient. In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification software. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis. A third FDA clearance was granted in 2020 for Viz ICH, which uses AI to automatically detect suspected intracranial hemorrhage on CT imaging. In 2020, CMS granted Viz.ai the first New Technology Add-on Payment (NTAP) for artificial intelligence software for Viz LVO.

Viz.ai is located in San Francisco and Tel Aviv and backed by leading Silicon Valley investors, including Kleiner Perkins, Google Ventures, Greenoaks, CRV, Threshold Ventures, Innovation Endeavors, Susa Ventures, Scale Venture Partners and Insight Partners.

Click here and find out more about Viz.ai.

29/06/202109/07/2024

Avicenna.AI Joins Nuance AI Marketplace, Offering Cutting-Edge Solutions for Diagnostic Imaging

Marseille, France – 29th June, 2021 – Avicenna.AI today announced that their FDA-cleared applications for neurovascular emergencies, CINA-ICH & CINA–LVO, are available on the Nuance® AI Marketplace, the first and largest portal with one-stop access to a wide range of AI diagnostic models from within the industry’s most widely used radiology reporting platform.

CINA offers radiologists an unparalleled solution for triaging patients with positive impact on high occurrence life-threatening pathologies. CINA-ICH and CINA-LVO automatically detect and prioritize acute intracranial hemorrhage and large vessel occlusion cases within 20 seconds, seamlessly alerting the radiologist within their existing systems and workflow.

The Nuance AI Marketplace functions like an app store dedicated to radiology. It gives algorithm developers consolidated, at-scale access to users of Nuance PowerScribe™, the radiology reporting system trusted by approximately 80 percent of U.S. radiologists across more than 9,000 connected healthcare facilities. Radiologists can discover, test, and use AI models from within their familiar Nuance PowerScribe reporting and workflow orchestration solutions to increase reporting efficiency and quality, and to help care teams improve patient outcomes and healthcare costs. A built-in feedback channel lets users share real-world results with developers for model refinement and post-market surveillance. Hospital systems benefit with simplified purchasing and metrics showing AI usage, costs, and performance.

“We are glad to partner with a global partner such as Nuance who shares our same values to put patient care at the core of their business. Together we are committed to transforming medical imaging by empowering radiologists in their daily tasks. Thanks to this partnership and our combined solutions, we aim to advance the future of healthcare,” said Cyril Di Grandi, Chief Executive Officer and co-founder of Avicenna.AI.

02/06/202103/07/2024

AI triage solution for deadly vascular conditions receives FDA clearance and CE Mark

Avicenna.AI announces the introduction of CINA-PE and CINA-AD, including AI tools for detection and emergency triage of pulmonary embolism and aortic dissection

Marseille, FRANCE – June 2, 2021 – Medical imaging AI specialist Avicenna.AI today announced that it has received certification in the United States and European Union for CINA-PE and CINA-AD, the new AI solutions that leverages deep learning algorithms for emergency triage of deadly vascular conditions.

In addition to securing a CE Mark in the EU, CINA-PE and CINA-AD have also received 510(k) clearance from the US Food and Drug Administration for its automatic detection and triage capabilities for both pulmonary embolism (PE) and aortic dissection (AD) from CT-scan imaging.our CINA solution.

Pulmonary embolism is the blockage of an artery in the lungs and is one of the major causes of death, morbidity, and hospitalization worldwide. It is difficult to diagnose PE as it manifests in diverse ways and can be mimicked by a range of other conditions. CINA CHEST provides rapid automatic PE detection on CT chest angiography, providing clinicians with accurate and rapid real-time alerts on the disease.

Aortic dissection is a tear in the inner layer of the aorta, allowing blood to flow between the layers. Although relatively rare, AD has a high mortality rate and is often not diagnosed when it first appears. Patients who receive the appropriate treatment in a timely manner have a high survival rate, so the importance of a quick and accurate diagnosis is critical. CINA CHEST identifies acute AD cases that require urgent intervention, providing accurate, real-time alerts on thoraco-abdominal CT angiography.

CINA CHEST is part of Avicenna’s CINA family of AI tools that support the treatment of emergencies, including CINA HEAD, its FDA-cleared and CE-Marked solution that supports the detection and triage of stroke and neurovascular emergencies.

“At Avicenna, we specialize in the development of AI algorithms that can identify acute abnormalities, and CINA CHEST is the latest application we’ve developed to enhance emergency room radiology,” said Cyril Di Grandi, co-founder and CEO of Avicenna.AI. “Our PE and AD triage tools are the third and fourth algorithms we’ve released in less than 12 months, demonstrating our ambition to create AI applications that support detection and triage of emergencies throughout the entire body.”

27/05/202103/07/2024

Avicenna.AI receives CE Mark for stroke severity assessment AI tool

Medical imaging AI innovator secures EU certification for CINA-ASPECTS, which helps quantify the severity of a stroke from a brain CT scan.

Marseille, FRANCE – May 27, 2021 – Medical imaging AI specialist Avicenna.AI today announced that it has received CE Mark certification for its CINA-ASPECTS AI tool for stroke severity assessment. CINA-ASPECTS automatically processes non-contrast CT scans and calculates the “ASPECT”score, assisting the radiologist within their existing systems and workflow.

ASPECTS, which stands for “Alberta Stroke Program Early CT Score” is a topographic scoring system used to quantify the severity of a stroke from a CT scan of the brain. It divides the brain territory affected by a stroke into 10 areas of interest and provides a score between zero and 10, where 10 is normal and zero indicates widespread ischemic damage throughout the affected area.

CINA-ASPECTS computes a heat map indicating the probability of hypodensity and/or sulcal effacement in the brain, and displays a list of infarcted regions. It also provides tilted and resliced CT images to allow easy comparison of the right and left hemispheres.

In addition to assisting clinicians to evaluate the ASPECT score from CT scans, CINA-ASPECTS also helps improve the reproducibility of the score, which often varies depending on the radiologist reading the scan.

CINA-ASPECTS is part of Avicenna.AI’s CINA Head family of AI tools that support the treatment of stroke and neurovascular emergencies. CINA Head also includes FDA-cleared and CE-Marked tools for detecting intracranial hemorrhages (ICHs) and large vessel occlusions (LVOs) from CT-scan imaging.

“CINA-ASPECTS supports stroke physicians and radiologists in the assessment and characterization of early ischemic brain tissue injury using CT image data,” said Cyril Di Grandi, co-founder, and CEO of Avicenna.AI.

“This new tool demonstrates our commitment to providing radiologists with AI solutions that can enhance their capabilities. Securing a CE Mark is a key milestone and we are delighted to be able to start offering the benefits of CINA-ASPECTS to our European customers – we look forward to FDA clearance in due course.”

01/12/202003/07/2024

Arterys & Avicenna.AI Join Forces on AI Stroke Detection

San Francisco, CA & Paris, FRANCE – December 1, 2020 – Medical imaging AI specialist Avicenna.AI today announced that its FDA-cleared CINA Head triage AI solution will be offered by cloud-based imaging platform Arterys. Supporting the treatment of stroke and neurovascular emergencies, CINA Head detects intracranial hemorrhages (ICHs) and large vessel occlusions (LVOs) from CT-scan imaging.

Arterys has fully integrated the CINA Head AI algorithms and will make them available via its FDA-cleared MICA platform to its installed base in the coming weeks. The platform’s cloud SaaS model enables CINA Head’s workflow-enhancing algorithms to be delivered instantly to any of Arterys’ existing customers.

“Given CMS’s recent NTAP reimbursement decision regarding AI-powered LVO detection, we believe that AI is finally ready to transform clinical practice, and we’re excited to make Avicenna’s AI innovations available to doctors around the world,” said John Axerio-Cilies, Arterys co-founder and CEO. “We’ve tuned the experience for seamless workflow integration—towards the ends of efficient and effective analysis of non-contrast head CTs and CTAs and accurate detection of intracranial hemorrhages and LVO strokes.”

“Arterys’s platform is the most agile in this new internet-based era of medical AI,” said Cyril Di Grandi, co-founder and CEO of Avicenna.AI. “They help companies like us go from code-to-clinic in weeks not years, giving radiologists the ability to instantly enhance their workflows with our AI – whenever they want to.”

About Arterys

Arterys is the market leader and the world’s first internet platform for medical imaging. Its objective is to transform healthcare by transforming radiology. The Arterys platform is 100% web-based, AI-powered, and FDA-cleared, unlocking simple clinical solutions. For more information on Arterys, please Arterys website.

Category: Press Release